Lars Erik Kristensen is chief scientific officer (CSO) at the parker institute. He operates as part leader and part doer with the responsibility of ensuring that the scientific projects support the strategy elements of the Parker Institute.
Lars Erik Kristensen is MD from the University of Copenhagen 2002, and specialist in internal medicine, rheumatology from Lund University, Sweden in 2009. Lars Erik Kristensen also defended his thesis in clinical rheumatology at Lund University in 2008.
Lars Erik Kristensens’ current research activities are focused around efficacy and tolerability of anti-TNF treatment and other 2nd generation biologicals in chronic arthritis both in controlled trial settings and observational cohort studies. Over the recent years, especially spondylarthritis have been studied also from an epidemiologic perspective. Exploring different outcome measures have gained increasing focus addressing interventions from a patient, societal, and clinical perspective.
Lars Erik Kristensen has ongoing research collaborations with the Karolinska Institute, Sahlgrenska University, and Diakonhjemmet in Oslo, and acts as associate professor at the department of rheumatology, Lund University, Sweden.